Subsequently, we conducted the review addressing the several drugs that target PD, from the multiple adenosine receptor A2A antagonists that have emerged as potential drug candidates to MAO-B and COMT inhibitors, showing that some molecules might improve the clinical efficiency of PD treatment in a near future. This evidence concerns the gene COMT and Parkinson disease.